文献速递乳腺MR

合成MRI预测不同乳腺癌亚型新辅助化疗后病理完全缓解的效用

Utility of synthetic MRI in predicting pathological complete response of various breast cancer subtypes prior to neoadjuvant chemotherapy.
PubMed 文献 · Clin Radiol · 2022-08-30

本研究回顾性纳入37例患者39个乳腺癌病灶,评估新辅助化疗前合成MRI定量参数预测病理完全缓解(pCR)的价值。多因素分析显示化疗前T2弛豫时间标准差(SD of Pre-T2)是pCR的独立预测因子,AUC为0.829,最佳截断值11.5时敏感度71.4%、特异度80%、准确率76.3%。作者认为该参数有预测潜力,但结果属初步,需进一步验证。

要点

  • 化疗前合成MRI的SD of Pre-T2是pCR独立预测因子,AUC 0.829。
  • SD of Pre-T2截断值11.5时,敏感度71.4%、特异度80%、准确率76.3%。
  • 该参数有望辅助新辅助化疗前筛选可能pCR的乳腺癌患者。

局限性

  • 回顾性研究设计。
  • 样本量较小(37例患者39个病灶)。
  • 作者指出结果为初步,需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To evaluate the usefulness of synthetic magnetic resonance imaging (MRI) performed before the initiation of neoadjuvant chemotherapy (NAC) in predicting whether breast cancers can achieve a pathological complete response (pCR) after the completion of NAC.

MATERIALS AND METHODS: This retrospective study investigated 37 consecutive patients with 39 breast cancers (pCR: 14, and non-pCR: 25) who underwent dynamic contrast-enhanced (DCE)-MRI and synthetic MRI before the initiation of NAC. Using synthetic MRI images, quantitative values (T1 and T2 relaxation times, proton density [PD] and their standard deviations [SD]) were obtained in breast lesions, before (Pre-T1, Pre-T2, Pre-PD, SD of Pre-T1, SD of Pre-T2, SD of Pre-PD) and after (Gd-T1, Gd-T2, Gd-PD, SD of Gd-T1, SD of Gd-T2, SD of Gd-PD) contrast agent injection. The aforementioned quantitative values and several morphological features that were identified on DCE-MRI were compared between pCR and non-pCR.

RESULTS: Multivariate analyses revealed that the SD of Pre-T2 (p=0.038) was significant and was an independent predictor of pCR, with an area under the receiver operating characteristics curve of 0.829. The sensitivity, specificity, and accuracy of the SD of Pre-T2 with an optimal cut-off value of 11.5 were 71.4%, 80%, and 76.3%, respectively.

CONCLUSIONS: The SD of Pre-T2 obtained from synthetic MRI was used successfully to predict those breast cancers that would achieve a pCR after the completion of NAC; however, these results are preliminary and need to be verified by further studies.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Matsuda, Fukuyama, Matsuda, et al. Utility of synthetic MRI in predicting pathological complete response of various breast cancer subtypes prior to neoadjuvant chemotherapy. Clin Radiol. 2022. PMID: 36055826. doi:10.1016/j.crad.2022.06.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。